West Pharmaceutical Services Statistics
Share Statistics
West Pharmaceutical Services has 72.42M shares outstanding. The number of shares has increased by -1.96% in one year.
Shares Outstanding | 72.42M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | -0.41% |
Owned by Institutions (%) | n/a |
Shares Floating | 71.99M |
Failed to Deliver (FTD) Shares | 3 |
FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 1.43M, so 1.98% of the outstanding shares have been sold short.
Short Interest | 1.43M |
Short % of Shares Out | 1.98% |
Short % of Float | 1.99% |
Short Ratio (days to cover) | 1.83 |
Valuation Ratios
The PE ratio is 44.09 and the forward PE ratio is 44.83. West Pharmaceutical Services 's PEG ratio is 6.91.
PE Ratio | 44.09 |
Forward PE | 44.83 |
PS Ratio | 8.87 |
Forward PS | 7.8 |
PB Ratio | 9.08 |
P/FCF Ratio | 63.12 |
PEG Ratio | 6.91 |
Enterprise Valuation
West Pharmaceutical Services Inc. has an Enterprise Value (EV) of 25.62B.
EV / Earnings | 43.17 |
EV / Sales | 8.68 |
EV / EBITDA | 30.35 |
EV / EBIT | 37.9 |
EV / FCF | 61.8 |
Financial Position
The company has a current ratio of 2.88, with a Debt / Equity ratio of 0.08.
Current Ratio | 2.88 |
Quick Ratio | 2.24 |
Debt / Equity | 0.08 |
Total Debt / Capitalization | 7.23 |
Cash Flow / Debt | 3.46 |
Interest Coverage | 75.11 |
Financial Efficiency
Return on equity (ROE) is 0.21% and return on capital (ROIC) is 17.48%.
Return on Equity (ROE) | 0.21% |
Return on Assets (ROA) | 0.15% |
Return on Capital (ROIC) | 17.48% |
Revenue Per Employee | 278.28K |
Profits Per Employee | 55.98K |
Employee Count | 10.60K |
Asset Turnover | 0.77 |
Inventory Turnover | 4.19 |
Taxes
Income Tax | 122.30M |
Effective Tax Rate | 0.18 |
Stock Price Statistics
The stock price has increased by -7.87% in the last 52 weeks. The beta is 1, so West Pharmaceutical Services 's price volatility has been higher than the market average.
Beta | 1 |
52-Week Price Change | -7.87% |
50-Day Moving Average | 311.55 |
200-Day Moving Average | 329.97 |
Relative Strength Index (RSI) | 59.79 |
Average Volume (20 Days) | 603.82K |
Income Statement
In the last 12 months, West Pharmaceutical Services had revenue of $2.95B and earned $593.40M in profits. Earnings per share was $7.99.
Revenue | 2.95B |
Gross Profit | 1.13B |
Operating Income | 676.00M |
Net Income | 593.40M |
EBITDA | 844.10M |
EBIT | 676.00M |
Earnings Per Share (EPS) | 7.99 |
Balance Sheet
The company has $853.90M in cash and $309.00M in debt, giving a net cash position of $544.90M.
Cash & Cash Equivalents | 853.90M |
Total Debt | 309.00M |
Net Cash | 544.90M |
Retained Earnings | 3.52B |
Total Assets | 3.68B |
Working Capital | 1.03B |
Cash Flow
In the last 12 months, operating cash flow was $776.50M and capital expenditures -$362.00M, giving a free cash flow of $414.50M.
Operating Cash Flow | 776.50M |
Capital Expenditures | -362.00M |
Free Cash Flow | 414.50M |
FCF Per Share | 5.58 |
Margins
Gross margin is 38.28%, with operating and profit margins of 22.92% and 20.12%.
Gross Margin | 38.28% |
Operating Margin | 22.92% |
Pretax Margin | 23.66% |
Profit Margin | 20.12% |
EBITDA Margin | 28.62% |
EBIT Margin | 22.92% |
FCF Margin | 14.05% |
Dividends & Yields
WST pays an annual dividend of $0.84, which amounts to a dividend yield of 0.25%.
Dividend Per Share | $0.84 |
Dividend Yield | 0.25% |
Dividend Growth (YoY) | 5% |
Payout Ratio | 12.44% |
Earnings Yield | 2.42% |
FCF Yield | 1.73% |
Analyst Forecast
The average price target for WST is $430, which is 30.3% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $430 |
Price Target Difference | 30.3% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Stock Splits
The last stock split was on Sep 27, 2013. It was a forward split with a ratio of 2:1.
Last Split Date | Sep 27, 2013 |
Split Type | forward |
Split Ratio | 2:1 |
Scores
Altman Z-Score | 18.1 |
Piotroski F-Score | 5 |